Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GPC3-CAR-T cells (Beijing Tsinghua Chang Gung Hospital)
- Development stage
- Unknown
- Lead developer
- Beijing Tsinghua Changgung Hospital
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
GPC3-CAR-T cells (Beijing Tsinghua Chang Gung Hospital) is an autologous chimeric antigen receptor (CAR) T-cell therapy currently in Phase I clinical development for the treatment of Glypican-3 (GPC3)-positive hepatocellular carcinoma (HCC). The therapy consists of T cells engineered to express a CAR targeting GPC3, a heparin sulfate proteoglycan that is overexpressed in the majority of HCC cases but absent in most healthy adult tissues. By targeting GPC3, the CAR-T cells are intended to selectively identify and eliminate malignant hepatocytes while sparing normal tissue. The clinical program, led by Beijing Tsinghua Chang Gung Hospital, evaluates the safety, tolerability, and preliminary efficacy of these cells following intravenous infusion in patients who have failed standard first-line therapies.
- Other names
- Glypican-3-targeted CAR-T cellsGlypican3-targeted CAR-T cellsGlypican 3-targeted CAR-T cellsGPC3-targeted chimeric antigen receptor T cellsGPC-3-targeted chimeric antigen receptor T cellsGPC 3-targeted chimeric antigen receptor T cells
02
Targets
GPC3 (Glypican-3)
Beyond the preview
Go deeper on GPC3-CAR-T cells (Beijing Tsinghua Chang Gung Hospital).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GPC3-CAR-T cells (Beijing Tsinghua Chang Gung Hospital).